In the wake of growing concerns over obesity and the inefficacy of drugs to treat this problem, many companies are coming ahead to give their best shot–no wonder that we have got something to listen fro Pfizer. The company says that two of its experimental obesity drugs have successfully reduced body weight, which makes the drugs to be compared to Acomplia–the famous drug used to treat obesity in Europe.

The weight loss achieved by these two drugs is around 4-6%, which is considerable in any amount of weight. It should be noticed that Acomplia has been approved for its use in Europe and is waiting to be cleared in US; and according to Pfizer, the results shown by their two drugs are as well as Acomplia could produce. The name of the drug is CP-945,598, which works through the same mechanism as Acomplia; and another one works through a different mechanism called MTP inhibtion.

The debate about obesity is growing hotter and hotter every day, and we can easily sense the urgency among the health or pharmaceutical companies about the discovery of new drugs that are potent to respond to the needs of patients who are suffering from obesity. The weight loss achieved by these drugs is a potential measure for their efficacy, which would be very helpful to make them popular among the crowd that is looking to have more variety of drugs that they can try.

Many have shown dissatisfaction over the efficacy of weight loss drugs and programs that are geared to provide solution to obesity. But till now, there is no drug in American market that can be given the status of a solution provider–customers have received very marginal or no benefit from the ones that there in the market. With the statements that Pfizer is making, we can expect that something beneficial will happen in the times to come.